JV-1-36 acetate is a growth hormone-releasing hormone (GHRH) antagonist. JV-1-36 acetate inhibits the production of reactive oxygen species in A549 lung cancer cells. JV-1-36 can be used to study the effect of GHRH antagonists in vitro .
JV-1-36 (0.01-15 μM; 8 h) reduces cell viability in A549 cells at higher concentrations (5-15 μM), and (2-15 μM; 8 h) also decreases cell viability in Hela cells[1].JV-1-36 (1 μM; 8 h) significantly reduces the production of ROS induced by H2O2 (0.1 mM; 8 h) in A549 lung cancer cells, exerting antioxidant effects[1].
References:
[1]. Kubra KT, et al. Growth Hormone-Releasing Hormone Antagonist JV-1-36 Suppresses Reactive Oxygen Species Generation in A549 Lung Cancer Cells. Endocrines. 2022 Dec;3(4):813-820.